Vickor Medical and Huazhong University of Science and Technology Awarded 2025 National Key R&D Program Grant for Transcatheter Mitral Valve Implantation Project

Recently, the project "Research on Key Technologies and Product Development Applications of Transcatheter Mitral Valve Implantation Devices" jointly submitted by Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") and Huazhong University of Science and Technology has undergone a rigorous review process.Approved for the 2025 National Key Research and Development Program "Diagnostic and Therapeutic Equipment and Biomedical Materials" Key Special Project. This breakthrough achievement not only represents high recognition of the technical strength and innovation capabilities of both parties but also marks a crucial step forward in the independent research and development path of China-produced high-end cardiovascular interventional devices.

The National Key R&D Program is a strategic vehicle for promoting technological self-reliance and breakthroughs in key core technologies of industries. Its sub-program "Medical Equipment and Biomedical Materials" directly addresses the health needs of the people, with the mission of overcoming advanced technologies and products in high-end medical equipment.Aimed at solving the "bottleneck" problems in China's medical device field, and enhance international competitiveness.

This approved project precisely targets the key pain points that urgently need to be addressed in clinical practice: meeting the treatment needs for severe mitral regurgitation, stenosis, or both, and overcoming core industry challenges such as "difficulty in anchoring" and "high risk of severe complications" during vascular interventional mitral valve replacement.Committed to the development of safe, efficient, and highly adaptable domestically-produced transcatheter mitral valve implantation devices, bringing new hope to patients with cardiovascular diseases.

This ProjectLed by Huazhong University of Science and Technology,Jointly promoted by Vickor, Yunnan Fuwai Cardiovascular Hospital, Institute of Metal Research of the Chinese Academy of Sciences, and Fuwai Hospital of the Chinese Academy of Medical Sciences，which has gathered top talents in the fields of medical R&D, clinical diagnosis and treatment, and material innovation, to build a full-chain collaborative system of "technology R&D - material support - clinical verification - industrialization implementation".

The project focuses on the frontier direction of transcatheter mitral valve replacement,Achieve Full-Chain Breakthroughs Through Four Major Projects: Starting with the 3D printing clinical system of Fuwai Hospital Yunnan Province to clarify needs and verification pathways; based on the material research from the Metal Research Institute to ensure long-term device safety; centered on Vickor's product development to achieve the leap from technology to product; and ultimately backed by the systematic evaluation of Fuwai Hospital Beijing to safeguard clinical translation. The four key projects are interlinked, forming an efficient closed loop.

Facing the clinical bottleneck of "difficult anchoring and high complications" in mitral valve interventional treatment, Vickor has taken on the heavy responsibility of product research and development and industrialization in the project. The company aims to achieve"Fatigue-resistant durability, easy anchoring, low complications"With the core goal of developing a full set of solutions covering valves, artificial rings, and delivery systems, promoting the early availability of safe and efficient domestically produced devices in clinical practice. The selection into China’s National Key Research and Development Program is a high recognition of the company's innovative strength. Vickor will take this as a new starting point, deepen industry-university-research cooperation, help achieve independent control of high-end medical devices, and contribute crucial strength to improving the diagnosis and treatment level of cardiovascular diseases.

Innovation-Driven Development, Technology Safeguards Life.Vickor is steadily paving a pragmatic path from technological breakthroughs to industrial implementation.It is expected that in the near future, this "Chinese heart" will beat powerfully across a broader field of life, bringing new hope to millions of patients.